Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Specificity of a UDP-GalNAc pyranose-furanose mutase: a potential therapeutic target for Campylobacter jejuni infections.

Poulin MB, Shi Y, Protsko C, Dalrymple SA, Sanders DA, Pinto BM, Lowary TL.

Chembiochem. 2014 Jan 3;15(1):47-56. doi: 10.1002/cbic.201300653. Epub 2013 Dec 2.

PMID:
24302429
2.

Elucidation of substrate specificity in Aspergillus nidulans UDP-galactose-4-epimerase.

Dalrymple SA, Ko J, Sheoran I, Kaminskyj SG, Sanders DA.

PLoS One. 2013 Oct 7;8(10):e76803. doi: 10.1371/journal.pone.0076803. eCollection 2013.

3.

Preliminary X-ray crystallographic studies of UDP-glucose-4-epimerase from Aspergillus nidulans.

Dalrymple SA, Sheoran I, Kaminskyj SG, Sanders DA.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2011 Aug 1;67(Pt 8):885-7. doi: 10.1107/S1744309111020914. Epub 2011 Jul 19.

4.

Discovery of 6-(2,4-difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)propylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (pamapimod) and 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2H-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (R1487) as orally bioavailable and highly selective inhibitors of p38α mitogen-activated protein kinase.

Goldstein DM, Soth M, Gabriel T, Dewdney N, Kuglstatter A, Arzeno H, Chen J, Bingenheimer W, Dalrymple SA, Dunn J, Farrell R, Frauchiger S, La Fargue J, Ghate M, Graves B, Hill RJ, Li F, Litman R, Loe B, McIntosh J, McWeeney D, Papp E, Park J, Reese HF, Roberts RT, Rotstein D, San Pablo B, Sarma K, Stahl M, Sung ML, Suttman RT, Sjogren EB, Tan Y, Trejo A, Welch M, Weller P, Wong BR, Zecic H.

J Med Chem. 2011 Apr 14;54(7):2255-65. doi: 10.1021/jm101423y. Epub 2011 Mar 4.

PMID:
21375264
5.

Identification and pre-clinical testing of a reversible cathepsin protease inhibitor reveals anti-tumor efficacy in a pancreatic cancer model.

Elie BT, Gocheva V, Shree T, Dalrymple SA, Holsinger LJ, Joyce JA.

Biochimie. 2010 Nov;92(11):1618-24. doi: 10.1016/j.biochi.2010.04.023. Epub 2010 May 4.

6.

Crystallization and preliminary X-ray studies of the N-domain of the Wilson disease associated protein.

Liu L, O'Grady C, Dalrymple SA, Prasad L, Dmitriev OY, Delbaere LT.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2009 Jun 1;65(Pt 6):621-4. doi: 10.1107/S1744309109017023. Epub 2009 May 22.

7.

Crystal engineering of a permanently porous network sustained exclusively by charge-assisted hydrogen bonds.

Dalrymple SA, Shimizu GK.

J Am Chem Soc. 2007 Oct 10;129(40):12114-6. Epub 2007 Sep 19. No abstract available.

PMID:
17880091
8.

Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase.

Pan Z, Scheerens H, Li SJ, Schultz BE, Sprengeler PA, Burrill LC, Mendonca RV, Sweeney MD, Scott KC, Grothaus PG, Jeffery DA, Spoerke JM, Honigberg LA, Young PR, Dalrymple SA, Palmer JT.

ChemMedChem. 2007 Jan;2(1):58-61. No abstract available.

PMID:
17154430
9.

CRA-026440: a potent, broad-spectrum, hydroxamic histone deacetylase inhibitor with antiproliferative and antiangiogenic activity in vitro and in vivo.

Cao ZA, Bass KE, Balasubramanian S, Liu L, Schultz B, Verner E, Dai Y, Molina RA, Davis JR, Misialek S, Sendzik M, Orr CJ, Leung L, Callan O, Young P, Dalrymple SA, Buggy JJ.

Mol Cancer Ther. 2006 Jul;5(7):1693-701.

10.

Evaluation of antitumor properties of novel saframycin analogs in vitro and in vivo.

Spencer JR, Sendzik M, Oeh J, Sabbatini P, Dalrymple SA, Magill C, Kim HM, Zhang P, Squires N, Moss KG, Sukbuntherng J, Graupe D, Eksterowicz J, Young PR, Myers AG, Green MJ.

Bioorg Med Chem Lett. 2006 Sep 15;16(18):4884-8. Epub 2006 Jul 25.

PMID:
16870445
11.

CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo.

Buggy JJ, Cao ZA, Bass KE, Verner E, Balasubramanian S, Liu L, Schultz BE, Young PR, Dalrymple SA.

Mol Cancer Ther. 2006 May;5(5):1309-17.

12.

Discovery of S-[5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxypropoxy)phenyl]methanone (RO3201195), an orally bioavailable and highly selective inhibitor of p38 MAP kinase.

Goldstein DM, Alfredson T, Bertrand J, Browner MF, Clifford K, Dalrymple SA, Dunn J, Freire-Moar J, Harris S, Labadie SS, La Fargue J, Lapierre JM, Larrabee S, Li F, Papp E, McWeeney D, Ramesha C, Roberts R, Rotstein D, San Pablo B, Sjogren EB, So OY, Talamas FX, Tao W, Trejo A, Villasenor A, Welch M, Welch T, Weller P, Whiteley PE, Young K, Zipfel S.

J Med Chem. 2006 Mar 9;49(5):1562-75.

PMID:
16509574
13.

Selective guest inclusion in a non-porous H-bonded host.

Dalrymple SA, Shimizu GK.

Chem Commun (Camb). 2006 Mar 7;(9):956-8. Epub 2006 Jan 24.

PMID:
16491174
14.

Structural constraints in the design of silver sulfonate coordination networks: three new polysulfonate open frameworks.

Hoffart DJ, Dalrymple SA, Shimizu GK.

Inorg Chem. 2005 Nov 28;44(24):8868-75.

PMID:
16296842
15.

3,3'-disubstituted BINAP ligands: synthesis, resolution, and applications in asymmetric hydrogenation.

Hopkins JM, Dalrymple SA, Parvez M, Keay BA.

Org Lett. 2005 Aug 18;7(17):3765-8.

PMID:
16092870
16.

Targeting B cells for the treatment of rheumatoid arthritis.

Oligino TJ, Dalrymple SA.

Arthritis Res Ther. 2003;5 Suppl 4:S7-11. Epub 2003 Oct 2. Review.

17.

Design and synthesis of 4-azaindoles as inhibitors of p38 MAP kinase.

Trejo A, Arzeno H, Browner M, Chanda S, Cheng S, Comer DD, Dalrymple SA, Dunten P, Lafargue J, Lovejoy B, Freire-Moar J, Lim J, Mcintosh J, Miller J, Papp E, Reuter D, Roberts R, Sanpablo F, Saunders J, Song K, Villasenor A, Warren SD, Welch M, Weller P, Whiteley PE, Zeng L, Goldstein DM.

J Med Chem. 2003 Oct 23;46(22):4702-13.

PMID:
14561090
18.

p38 mitogen activated protein kinase as a therapeutic target for Alzheimer's disease.

Dalrymple SA.

J Mol Neurosci. 2002 Dec;19(3):295-9. Review.

PMID:
12540055
20.

Anion exchange in the channels of a robust alkaline earth sulfonate coordination network.

Dalrymple SA, Shimizu GK.

Chemistry. 2002 Jul 2;8(13):3010-5.

PMID:
12489232
21.

An open channel coordination framework sustained by cooperative primary and secondary sphere interactions.

Dalrymple SA, Shimizu GK.

Chem Commun (Camb). 2002 Oct 7;(19):2224-5.

PMID:
12397989
22.

A small molecule ubiquitination inhibitor blocks NF-kappa B-dependent cytokine expression in cells and rats.

Swinney DC, Xu YZ, Scarafia LE, Lee I, Mak AY, Gan QF, Ramesha CS, Mulkins MA, Dunn J, So OY, Biegel T, Dinh M, Volkel P, Barnett J, Dalrymple SA, Lee S, Huber M.

J Biol Chem. 2002 Jun 28;277(26):23573-81. Epub 2002 Apr 11.

23.

Intercalation of alcohols in Ag sulfonates: topotactic behavior despite flexible layers.

Côté AP, Ferguson MJ, Khan KA, Enright GD, Kulynych AD, Dalrymple SA, Shimizu GK.

Inorg Chem. 2002 Jan 28;41(2):287-92.

PMID:
11800616
24.

Models of inflammation: adjuvant-induced arthritis in the rat.

Whiteley PE, Dalrymple SA.

Curr Protoc Pharmacol. 2001 Aug;Chapter 5:Unit5.5. doi: 10.1002/0471141755.ph0505s13.

PMID:
21959761
25.

Models of inflammation: measuring gastrointestinal ulceration in the rat.

Whiteley PE, Dalrymple SA.

Curr Protoc Pharmacol. 2001 May;Chapter 10:Unit 10.2. doi: 10.1002/0471141755.ph1002s00. No abstract available.

PMID:
21971793
26.

NF-kappa B activation by tumor necrosis factor and interleukin-1.

Cao Z, Tanaka M, Regnier C, Rothe M, Yamit-hezi A, Woronicz JD, Fuentes ME, Durnin MH, Dalrymple SA, Goeddel DV.

Cold Spring Harb Symp Quant Biol. 1999;64:473-83. Review. No abstract available.

PMID:
11232324
27.

Embryonic lethality, liver degeneration, and impaired NF-kappa B activation in IKK-beta-deficient mice.

Tanaka M, Fuentes ME, Yamaguchi K, Durnin MH, Dalrymple SA, Hardy KL, Goeddel DV.

Immunity. 1999 Apr;10(4):421-9.

28.

Testosterone and IL-6 requirements for human C-reactive protein gene expression in transgenic mice.

Szalai AJ, van Ginkel FW, Dalrymple SA, Murray R, McGhee JR, Volanakis JE.

J Immunol. 1998 Jun 1;160(11):5294-9.

29.

The cytokine stew and innate resistance to L. monocytogenes.

Mocci S, Dalrymple SA, Nishinakamura R, Murray R.

Immunol Rev. 1997 Aug;158:107-14. Review.

PMID:
9314078
30.

Impaired resistance to the development of toxoplasmic encephalitis in interleukin-6-deficient mice.

Suzuki Y, Rani S, Liesenfeld O, Kojima T, Lim S, Nguyen TA, Dalrymple SA, Murray R, Remington JS.

Infect Immun. 1997 Jun;65(6):2339-45.

31.

Interleukin-6 is required for a protective immune response to systemic Escherichia coli infection.

Dalrymple SA, Slattery R, Aud DM, Krishna M, Lucian LA, Murray R.

Infect Immun. 1996 Aug;64(8):3231-5.

32.

Regulation of interleukin-6, osteoclastogenesis, and bone mass by androgens. The role of the androgen receptor.

Bellido T, Jilka RL, Boyce BF, Girasole G, Broxmeyer H, Dalrymple SA, Murray R, Manolagas SC.

J Clin Invest. 1995 Jun;95(6):2886-95.

33.

Interleukin-6-deficient mice are highly susceptible to Listeria monocytogenes infection: correlation with inefficient neutrophilia.

Dalrymple SA, Lucian LA, Slattery R, McNeil T, Aud DM, Fuchino S, Lee F, Murray R.

Infect Immun. 1995 Jun;63(6):2262-8.

34.
35.

Implications of a study in nurse-physician relationship.

Dalrymple SA, Pierce CM, Brotzman E, Graves N, Hofling CK.

Nurs Forum. 1968 Winter;7(1):21-7. No abstract available.

PMID:
5184933

Supplemental Content

Loading ...
Support Center